A mouse model suggests two mechanisms for thyroid alterations in infantile cystinosis: Decreased thyroglobulin synthesis due to endoplasmic reticulum stress/unfolded protein response and impaired lysosomal processing

Endocrinology

Volumn 156, Issue 6, 2015, Pages 2349-2364

  Gaide Chevronnay, H P ^a   Janssens, V ^a   Van Der Smissen, P ^a   Liao, X H ^b   Abid, Y ^a   Nevo, N ^c   Antignac, C ^c   Refetoff, S ^b   Cherqui, S ^d   Pierreux, C E ^a   Courtoy, P J ^a  

^a DE DUVE INSTITUTE   (Belgium)

^b UNIVERSITY OF CHICAGO   (United States)

^c INSERM   (France)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; CATHEPSIN B; CHAPERONE; CYSTINE; GLUCOSE REGULATED PROTEIN; LIOTHYRONINE; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; PROTEIN DISULFIDE ISOMERASE; THYROGLOBULIN; THYROTROPIN; THYROXINE; X BOX BINDING PROTEIN 1; AMINO ACID TRANSPORTER; CYSTINOSIN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY LABELING; APOPTOSIS; ARTICLE; CELL FRACTIONATION; CELL PROLIFERATION; COLLOID; CYSTINOSIS; DISEASE COURSE; DOWN REGULATION; ELECTRON MICROSCOPY; ENDOPLASMIC RETICULUM STRESS; HISTOLOGY; HORMONE RELEASE; HYPERPLASIA; HYPERTROPHY; HYPOTHYROIDISM; INFANTILE CYSTINOSIS; LIOTHYRONINE BLOOD LEVEL; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; PROTEIN UNFOLDING; RNA SPLICING; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TURNOVER TIME; UNFOLDED PROTEIN RESPONSE; ANIMAL; BIOSYNTHESIS; FEMALE; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

AMINO ACID TRANSPORT SYSTEMS, NEUTRAL; ANIMALS; CYSTINOSIS; ENDOPLASMIC RETICULUM STRESS; FEMALE; LYSOSOMES; MALE; MICE; THYROGLOBULIN; UNFOLDED PROTEIN RESPONSE;

EID: 84930446736     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1672     Document Type: Article

References (82)

1. Van Vliet G. Development of the thyroid gland: lessons from congenitally hypothyroid mice and men. Clin Genet. 2003;63(6):445-455.
2. Grasberger H, Refetoff S. Congenital defects of thyroid hormone synthesis. In: Weiss RE, Refetoff S. eds. Genetics Diagnosis of Endocrine Disorders. Amsterdam, The Netherlands: Academic Press, Elsevier, Inc; 2010:87-95.
3. Gahl WA, Thoene JG, Schneider JA. Cystinosis. N Engl J Med. 2002;347(2):111-121.
4. th ed. New York: McGraw-Hill Companies, Inc; 2001:5085-5108. Online update 2013.
5. Chan AM, Lynch MJ, Bailey JD, Ezrin C, Fraser D. Hypothyroidism in cystinosis. A clinical, endocrinologic and histologic study involving sixteen patients with cystinosis. Am J Med. 1970;48(6):678-692.
6. Broyer M, Niaudet P. Cystinosis. In: Saudubray JM, van den Berghe G, Walter JH, eds. Inborn Metabolic Diseases: Berlin Heidelberg: Springer; 2012:617-624.
7. Cherqui S, Kalatzis V, Trugnan G, Antignac C. The targeting of cystinosin to the lysosomal membrane requires a tyrosine-based signal and a novel sorting motif. J Biol Chem. 2001;276(16):13314-13321.
8. Kalatzis V, Cherqui S, Antignac C, Gasnier B. Cystinosin, the protein defective in cystinosis, is a H(+)-driven lysosomal cystine transporter. EMBO J. 2001;20(21):5940-5949.
9. Jezegou A, Llinares E, Anne C, et al. Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy. Proc Natl Acad Sci USA. 2012;109(50):E3434-E3443.
10. Lucky AW, Howley PM, Megyesi K, Spielberg SP, Schulman JD. Endocrine studies in cystinosis: compensated primary hypothyroidism. J Pediatr. 1977;91(2):204-210.
11. Kimonis VE, Troendle J, Rose SR, Yang ML, Markello TC, Gahl WA. Effects of early cysteamine therapy on thyroid function and growth in nephropathic cystinosis. J Clin Endocrinol Metab. 1995;80(11):3257-3261.
12. Brodin-Sartorius A, Tete MJ, Niaudet P, et al. Cysteamine therapy delays the progression of nephropathic cystinosis in late adolescents and adults. Kidney Int. 2012;81(2):179-189.
13. Emma F, Nesterova G, Langman C, et al. Nephropathic cystinosis: an international consensus document. Nephrol Dialysis Transplant. 2014;29(suppl 4):iv87-94.
14. Pisoni RL, Acker TL, Lisowski KM, Lemons RM, Thoene JG. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J Cell Biol. 1990;110(2):327-335.
15. Brix K, Lemansky P, Herzog V. Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology. 1996;137(5):1963-1974.
16. Friedrichs B, Tepel C, Reinheckel T, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest. 2003;111(11):1733-1745.
17. Edelhoch H, Rall J. The proteins and enzymes of the thyroid In: Pitt-Rivers R, Trotter W, eds. The Thyroid Gland. London: Butterworths; 1964:113-130.
18. Herzog V, Berndorfer U, Saber Y. Isolation of insoluble secretory product from bovine thyroid: extracellular storage of thyroglobulin in covalently cross-linked form. J Cell Biol. 1992;118(5):1071-1083.
19. Gerard AC, Denef JF, Colin IM, van den Hove MF. Evidence for processing of compact insoluble thyroglobulin globules in relation with follicular cell functional activity in the human and the mouse thyroid. Eur J Endocrinol. 2004;150(1):73-80.
20. Klein M, Gestmann I, Berndorfer U, Schmitz A, Herzog V. The thioredoxin boxes of thyroglobulin: possible implications for intermolecular disulfide bond formation in the follicle lumen. Biol Chem. 2000;381(7):593-601.
21. Berndorfer U, Wilms H, Herzog V. Multimerization of thyroglobulin (TG) during extracellular storage: isolation of highly crosslinked TG from human thyroids. J Clin Endocrinol Metab. 1996;81(5):1918-1926.
22. Peake BL, Balasubramaniam K, Deiss WP. Effect of reduced glutathione on the proteolysis of intraparticulate and native thyroglobulin. Biochim Biophys Acta. 1967;148:689-702.
23. Yoshinari M, Taurog A. Lysosomal digestion of thyroglobulin: role of cathepsin D and thiol proteases. Endocrinology. 1985;117(4):1621-1631.
24. Dunn AD, Dunn JT. Cysteine proteinases from human thyroids and their actions on thyroglobulin. Endocrinology. 1988;123(2):1089-1097.
25. Dunn AD, Crutchfield HE, Dunn JT. Proteolytic processing of thyroglobulin by extracts of thyroid lysosomes. Endocrinology. 1991;128(6):3073-3080.
26. Dunn AD, Myers HE, Dunn JT. The combined action of two thyroidal proteases releases T4 from the dominant hormone-forming site of thyroglobulin. Endocrinology. 1996;137(8):3279-3285.
27. Nakagawa H, Ohtaki S. Thyroxine (T4) release from thyroglobulin and its T4-containing peptide by thyroid thiol proteases. Endocrinology. 1985;116(4):1433-1439.
28. Marino M, McCluskey RT. Role of thyroglobulin endocytic pathways in the control of thyroid hormone release. Am J Physiol Cell Physiol. 2000;279(5):C1295-C1306.
29. Croizet-Berger K, Daumerie C, Couvreur M, Courtoy PJ, van den Hove MF. The endocytic catalysts, Rab5a and Rab7, are tandem regulators of thyroid hormone production. Proc Natl Acad Sci USA. 2002;99(12):8277-8282.
30. van den Hove MF, Croizet-Berger K, Tyteca D, Selvais C, de Diesbach P, Courtoy PJ. Thyrotropin activates guanosine 5′-diphosphate/guanosine 5′-triphosphate exchange on the rate-limiting endocytic catalyst, Rab5a, in human thyrocytes in vivo and in vitro. J Clin Endocrinol Metab. 2007;92(7):2803-2810.
31. Fujita H. Functional morphology of the thyroid. Int Rev Cytol. 1988;113:145-185.
32. Di Cosmo C, Liao XH, Dumitrescu AM, Philp NJ, Weiss RE, Refetoff S. Mice deficient in MCT8 reveal a mechanism regulating thyroid hormone secretion. J Clin Invest. 2010;120(9):3377-3388.
33. Gaide Chevronnay HP, Janssens V, Van Der Smissen P, et al. Time course of pathogenic and adaptation mechanisms in cystinotic mouse kidneys. J Am Soc Nephrol. 2014;25(6):1256-1269.
34. Raggi C, Luciani A, Nevo N, Antignac C, Terryn S, Devuyst O. Dedifferentiation and aberrations of the endolysosomal compartment characterize the early stage of nephropathic cystinosis. Hum Mol Genet. 2014;23(9):2266-2278.
35. Cherqui S, Sevin C, Hamard G, et al. Intralysosomal cystine accumulation in mice lacking cystinosin, the protein defective in cystinosis. Mol Cell Biol. 2002;22(21):7622-7632.
36. Nevo N, Chol M, Bailleux A, et al. Renal phenotype of the cystinosis mouse model is dependent upon genetic background. Nephrol Dialysis Transpl. 2010;25(4):1059-1066.
37. Johnson JL, Napolitano G, Monfregola J, Rocca CJ, Cherqui S, Catz SD. Upregulation of the Rab27a-dependent trafficking and secretory mechanisms improves lysosomal transport, alleviates endoplasmic reticulum stress, and reduces lysosome overload in cystinosis. Mol Cell Biol. 2013;33(15):2950-2962.
38. Baryshev M, Sargsyan E, Wallin G, et al. Unfolded protein response is involved in the pathology of human congenital hypothyroid goiter and rat non-goitrous congenital hypothyroidism. J Mol Endocrinol. 2004;32(3):903-920.
39. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Bio. 2012;13(2):89-102.
40. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006;7(9):880-885.
41. Pohlenz J, Maqueem A, Cua K, Weiss RE, Van Sande J, Refetoff S. Improved radioimmunoassay for measurement of mouse thyrotropin in serum: strain differences in thyrotropin concentration and thyrotroph sensitivity to thyroid hormone. Thyroid. 1999;9(12):1265-1271.
42. Pierreux CE, Cordi S, Hick AC, et al. Epithelial: endothelial crosstalk regulates exocrine differentiation in developing pancreas. Dev Biol. 2010;347(1):216-227.
43. Gaide Chevronnay HP, Cornet PB, Delvaux D, et al. Opposite regulation of transforming growth factors-β2 and -β3 expression in the human endometrium. Endocrinology. 2008;149(3):1015-1025.
44. Zachara NE, Vosseller K, Hart GW. Detection and analysis of proteins modified by O-linked N-acetylglucosamine. Curr Protoc Protein Sci. 2011;Chapter 12:Unit12.8.
45. Barrett AJ. Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates. Biochem J. 1980;187(3):909-912.
46. Colin IM, Denef JF, Lengele B, Many MC, Gerard AC. Recent insights into the cell biology of thyroid angiofollicular units. Endocr Rev. 2013;34(2):209-238.
47. Coclet J, Foureau F, Ketelbant P, Galand P, Dumont JE. Cell population kinetics in dog and human adult thyroid. Clin Endocrinol (Oxf). 1989;31(6):655-665.
48. Park MA, Thoene JG. Potential role of apoptosis in development of the cystinotic phenotype. Pediatr Nephrol. 2005;20(4):441-446.
49. Sansanwal P, Kambham N, Sarwal MM. Caspase-4 may play a role in loss of proximal tubules and renal injury in nephropathic cystinosis. Pediatr Nephrol. 2010;25(1):105-109.
50. Leonardi A, Vito P, Mauro C, et al. Endoplasmic reticulum stress causes thyroglobulin retention in this organelle and triggers activation of nuclear factor-κB via tumor necrosis factor receptor-associated factor 2. Endocrinology. 2002;143(6):2169-2177.
51. Sansanwal P, Li L, Hsieh SC, Sarwal MM. Insights into novel cellular injury mechanisms by gene expression profiling in nephropathic cystinosis. J Inherit Metab Dis. 2010;33(6):775-786.
52. Oslowski CM, Urano F. Measuring ER stress and the unfolded protein response using mammalian tissue culture system. Methods Enzymol. 2011;490:71-92.
53. Samali A, Fitzgerald U, Deegan S, Gupta S. Methods for monitoring endoplasmic reticulum stress and the unfolded protein response. Int J Cell Biol. 2010;2010:830307.
54. Hick AC, Delmarcelle AS, Bouquet M, et al. Reciprocal epithelial: endothelial paracrine interactions during thyroid development govern follicular organization and C-cells differentiation. Dev Biol. 2013;381(1):227-240.
55. Ramsden JD, Buchanan MA, Egginton S, Watkinson JC, Mautner V, Eggo MC. Complete inhibition of goiter in mice requires combined gene therapy modification of angiopoietin, vascular endothelial growth factor, and fibroblast growth factor signaling. Endocrinology. 2005;146(7):2895-2902.
56. Imada M, Kurosumi M, Fujita H. Three-dimensional aspects of blood vessels in thyroids from normal, low iodine diet-treated, TSH-treated, and PTU-treated rats. Cell Tissue Res. 1986;245(2):291-296.
57. Van Herle AJ, Vassart G, Dumont JE. Control of thyroglobulin synthesis and secretion (first of two parts). N Engl J Med. 1979;301(5):239-249.
58. Van Heuverswyn B, Streydio C, Brocas H, Refetoff S, Dumont J, Vassart G. Thyrotropin controls transcription of the thyroglobulin gene. Proc Natl Acad Sci USA. 1984;81(19):5941-5945.
59. Van Heuverswyn B, Leriche A, Van Sande J, Dumont JE, Vassart G. Transcriptional control of thyroglobulin gene expression by cyclic AMP. FEBS Lett. 1985;188(2):192-196.
60. Kim PS, Lee J, Jongsamak P, et al. Defective protein folding and intracellular retention of thyroglobulin-R19K mutant as a cause of human congenital goiter. Mol Endocrinol. 2008;22(2):477-484.
61. Kim PS, Bole D, Arvan P. Transient aggregation of nascent thyroglobulin in the endoplasmic reticulum: relationship to the molecular chaperone, BiP. J Cell Biol. 1992;118(3):541-549.
62. Kim PS, Arvan P. Calnexin and BiP act as sequential molecular chaperones during thyroglobulin folding in the endoplasmic reticulum. J Cell Biol. 1995;128(1-2):29-38.
63. Di Jeso B, Park YN, Ulianich L, et al. Mixed-disulfide folding intermediates between thyroglobulin and endoplasmic reticulum resident oxidoreductases ERp57 and protein disulfide isomerase. Mol Cell Biol. 2005;25(22):9793-9805.
64. Levtchenko E, de Graaf-Hess A, Wilmer M, van den Heuvel L, Monnens L, Blom H. Altered status of glutathione and its metabolites in cystinotic cells. Nephrol Dialysis Transpl. 2005;20(9):1828-1832.
65. Levtchenko EN, Wilmer MJ, Janssen AJ, et al. Decreased intracellular ATP content and intact mitochondrial energy generating capacity in human cystinotic fibroblasts. Pediatr Res. 2006;59(2):287-292.
66. Medeiros-Neto G, Kim PS, Yoo SE, et al. Congenital hypothyroid goiter with deficient thyroglobulin. Identification of an endoplasmic reticulum storage disease with induction of molecular chaperones. J Clin Invest. 1996;98(12):2838-2844.
67. Kim PS, Kwon OY, Arvan P. An endoplasmic reticulum storage disease causing congenital goiter with hypothyroidism. J Cell Biol. 1996;133(3):517-527.
68. Christis C, Fullaondo A, Schildknegt D, Mkrtchian S, Heck AJ, Braakman I. Regulated increase in folding capacity prevents unfolded protein stress in the ER. J Cell Sci. 2010;123(Pt 5):787-794.
69. Sriburi R, Jackowski S, Mori K, Brewer JW. XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J Cell Biol. 2004;167(1):35-41.
70. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity. 2004;21(1):81-93.
71. Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003;23(21):7448-7459.
72. Wei H, Kim SJ, Zhang Z, Tsai PC, Wisniewski KE, Mukherjee AB. ER and oxidative stresses are common mediators of apoptosis in both neurodegenerative and non-neurodegenerative lysosomal storage disorders and are alleviated by chemical chaperones. Hum Mol Genet. 2008;17(4):469-477.
73. Schulman JD, Bradley KH, Seegmiller JE. Cystine: compartmentalization within lysosomes in cystinotic leukocytes. Science. 1969;166(3909):1152-1154.
74. Pisarev MA, Dumont JE. The role of reduced glutathione in thyroglobulin proteolysis iv vitro. Acta Endocrinol. 1975;79(1):76-85.
75. Dunn AD, Dunn JT. Thyroglobulin degradation by thyroidal proteases: action of purified cathepsin D. Endocrinology. 1982;111(1):280-289.
76. Faggiano A, Pisani A, Milone F, et al. Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab. 2006;91(11):4319-4325.
77. Hauser AC, Gessl A, Lorenz M, Voigtlander T, Fodinger M, Sunder-Plassmann G. High prevalence of subclinical hypothyroidism in patients with Anderson-Fabry disease. J Inherit Metab Dis. 2005;28(5):715-722.
78. Polgreen LE, Tolar J, Plog M, et al. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2008;41(12):1005-1011.
79. Syres K, Harrison F, Tadlock M, et al. Successful treatment of the murine model of cystinosis using bone marrow cell transplantation. Blood. 2009;114(12):2542-2552.
80. Yeagy BA, Harrison F, Gubler MC, Koziol JA, Salomon DR, Cherqui S. Kidney preservation by bone marrow cell transplantation in hereditary nephropathy. Kidney Int. 2011;79(11):1198-1206.
81. Harrison F, Yeagy BA, Rocca CJ, Kohn DB, Salomon DR, Cherqui S. Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther. 2013;21(2):433-444.
82. Naphade S, Sharma J, Gaide Chevronnay HP, et al. Brief reports: lysosomal cross-correction by hematopoietic stem cell-derived macrophages via tunneling nanotubes. Stem Cells. 2015;33(1):301-309.